DC-U4106 is a USP8 targeting inhibitor with the K d value of 4.7 μM and the IC 50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα . DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer
In Vitro
DC-U4106 (1.2-45.2 μM) inhibits USP8 and USP2 with the IC 50 values of 1.2 μM and 58.4 μM, respectively, and no activity in USP7. DC-U4106 (0-7 μM, 24 hours) reduces mRNA levels of ERα and PR. DC-U4106 (0-5 μM, 24 hours) can regulate the RTK pathway related proteins and the expression of ERα and PR proteins. DC-U4106 (0-5 μM, 12 hours) can induce apoptosis and inhibit cell proliferation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: USP8-positive cell line MCF-7 Concentration: 0-5 μM Incubation Time: 24 hours Result: Reduced the expression of EGFR, ErbB2, and ErbB3 proteins with increasing concentrations and caused degradation of ERα and PR proteins. RT-PCRCell Line: USP8-positive cell line MCF-7 Concentration: 0-7 μM Incubation Time: 24 hours Result: Reduced mRNA levels of ERα and PR. Cell Proliferation AssayCell Line: USP8-positive cell line MCF-7 Concentration: 0-5 μM Incubation Time: Result: Inhibited cell growth in a dose-dependent manner. Apoptosis AnalysisCell Line: USP8-positive cell line MCF-7 Concentration: 0-5 μM Incubation Time: 12 hours Result: Resulted in increasing in the proportion of apoptotic cells with increasing concentrations.
In Vivo
DC-U4106 (intraperitoneal injection, 5 mg/kg or 20 mg/kg, every 2 days, 14 days) inhibits the proliferation of tumors and no significantly effects on body weight, organ morphology and structure in BALB/c nude mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c nude mice Dosage: 5 mg/kg , 20 mg/kg Administration: Intraperitoneal injection, Every 2 days, 14 days Result: Inhibited tumor growth significantly at a concentration of 20 mg/kg.
DC-U4106 is a USP8 targeting inhibitor with the K d value of 4.7 μM and the IC 50 value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα . DC-U4106 inhibits tumor growth with minimal toxicity and has the potential
保管条件
Store at 2-8°C,Protected from light,Desiccated
入荷
Wet ice
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
アクションタイプ
INHIBITOR
純度
≥99%
名前と識別子
分子量
525.56
詳細データ
証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
化学的性質と物理的性質
溶解度
THF : 10 mg/mL (19.03 mM; Need ultrasonic)
ソリューション計算機
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
レビュー
顧客レビュー
Application Protocols
No tested application data are provided for this item. The following general procedures are commonly used for small-molecule screening compounds.
Stock preparation: Dissolve compound in anhydrous DMSO to 10–50 mM. Vortex and, if necessary, sonicate briefly. Record any undissolved solids.
Aliquoting: Dispense into amber, low-bind tubes/plates to minimize adsorption and protect from light. Avoid repeated freeze–thaw by preparing single-use aliquots.
HTS plating: Perform serial dilutions in DMSO, then back-dilute into assay buffer to reach desired final concentration with ≤1% DMSO.
Controls: Include vehicle controls and known positive/negative controls relevant to the assay technology (enzymatic, binding, cell-based).
Interference checks: Assess autofluorescence/absorbance in the detection window, and test for detergent-sensitive inhibition to flag aggregators.
Analytics: Confirm well concentrations by LC-UV/MS when quantitative accuracy is critical. Monitor for precipitation or carryover on instruments.
These are general guidelines; adapt to your assay format and institutional SOPs.
Biological Roles
No biological role, pathway association, or target information is provided for this screening compound.
General considerations for screening molecules:
These entities are typically synthetic and do not have established endogenous biological roles.
Any observed biological activity in assays should be treated as putative until validated by orthogonal methods (counter-screens, secondary assays, selectivity panels).
Prior to mechanistic claims, evaluate common liabilities: PAINS, redox cycling, colloidal aggregation, and metal chelation.
If the structure becomes available, computational annotation (similarity to known ligands, chemogenomic predictions) can suggest hypotheses for target deconvolution (e.g., CETSA, DARTS, photoaffinity probes).
Note: All uses are for research only; no clinical or diagnostic claims are made.
Buffer Applications
This product is not a buffering agent and no pKa information is provided.
Practical notes for assay buffers (general handling of screening compounds):
Prepare concentrated DMSO stock solutions and dilute into assay buffers immediately before use. Maintain final DMSO ≤0.5–1% v/v to minimize effects on enzymes/cells.
Use standard biological buffers compatible with your assay (e.g., HEPES, PBS, Tris) and confirm that the compound does not precipitate upon dilution. Brief sonication can aid dissolution.
Include vehicle controls (matching DMSO %) and, when appropriate, detergent (e.g., 0.01–0.05% Tween-20) to suppress nonspecific aggregation.
Filter buffers (0.22–0.45 µm) to reduce particulates that can confound readouts (light scattering, turbidity).
Green Alternatives
Without a defined structure or application, green chemistry discussion centers on solvent and process choices during handling and analysis.
Greener practice suggestions (general):
Prefer EtOH, i-PrOH, or MeOH over chlorinated solvents for cleaning and sample preparation when compatible with the compound.
For stock solutions, DMSO is often unavoidable for diverse chemotypes; minimize volumes and carryover in assays. Where feasible, explore propylene carbonate or 2-MeTHF for non-biological processing.
Use ACN:H2O gradients instead of MeCN:MeOH blends to reduce solvent diversity and simplify waste streams.
Scale analytical injections to micro-flow/UPLC to reduce solvent consumption.
Illustrative comparison (general):
DMSO vs. DMF/NMP: DMSO is typically preferred due to lower toxicity and better biodegradability profiles.
2-MeTHF/EtOAc vs. dichloromethane for workups: choose ethers/esters where compatible with stability.
Caveat: Final solvent and process selection should be guided by the compound’s actual structure and stability profile once available.
Pharmaceutical Uses
No pharmacopeial status, excipient role, or formulation guidance is provided for this item, and it is designated For research use only.
General notes relevant to pre-formulation research (non-clinical):
For early discovery PK/PD studies in research animals (if permitted institutionally), solvent systems often include DMSO:PEG400:saline or Captisol; compatibility must be established once the structure and stability are known. This listing does not supply such guidance and does not imply suitability.
Determine solution stability, pH sensitivity, and light/moisture sensitivity experimentally before any formulation exploration.
No therapeutic or clinical claims are made. This product is not intended for human or veterinary use.
Physical Properties
Item-specific physicochemical data have not been provided for this catalog entry.
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Melting point / Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
Density / Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
Solubility profile (water/organic): Not specified for this item; refer to CoA/Spec Sheet.
LogP / pKa: Not specified for this item; refer to CoA/Spec Sheet.
Practical notes (general, literature-level guidance for small-molecule screening compounds):
Most screening compounds are provided as dry powders or dried films and are commonly reconstituted in anhydrous DMSO to prepare 10–50 mM stocks. Actual solubility depends on the structure; verify experimentally.
If aqueous use is intended, perform a solubility screen: DMSO, DMF, MeOH, EtOH, then buffered aqueous media with co-solvent (typically 0.1–1% DMSO final in assay). Check for precipitation after dilution.
Measure concentration by UV–Vis if a strong chromophore exists (obtain ε from literature or determine empirically), or by quantitative NMR/LC-UV.
Record any polymorphism or hydrates if observed; these can shift apparent melting points and solubility.
Quality and Grades
Item-specific grade and purity are not listed in the current entry.
Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
Interpretation and expectations (general for screening compounds):
Screening library members are typically provided at research-grade purity, frequently ≥95% by HPLC/LC-MS unless otherwise specified. Verify with the accompanying CoA (look for assay, purity, and residual solvent/water content methods).
If optical activity is relevant, check for enantiomeric/excess reporting (chiral HPLC). For racemates, document the mixture ratio for SAR.
If stabilizers or counter-ions are present, they will be listed on the CoA. The current listing contains no stabilizer information.
For analytical work, consider performing an incoming QC: orthogonal purity check (HPLC-UV at multiple wavelengths, LC-MS), identity confirmation (HRMS/1H NMR), and water/volatile content (Karl Fischer/GC).
Documentation to request for regulated or data-critical studies:
Batch-specific CoA, spectral package (1H/13C NMR, MS), and chromatogram(s), plus salt/form information (free base vs. HCl, etc.).
Reaction and Applications
This catalog entry is positioned as a small-molecule screening compound. No item-specific reactivity or application claims are provided.
Research-use contexts (general):
Primary use: Inclusion in HTS, fragment- or lead-finding campaigns, and SAR development as a chemical probe candidate. Applicable to biochemical, biophysical, and cell-based assays after verifying solubility and stability.
Orthogonal profiling: Evaluate for assay interference (autofluorescence, redox cycling, metal chelation, aggregation) before interpreting potency.
Follow-up chemistry: If the structure is available, analog expansion and vector scans enable rapid SAR to optimize potency, selectivity, and ADME properties.
Analytical tips:
Build a compound dossier: purity (HPLC at multiple wavelengths), identity (HRMS/NMR), stability (freeze–thaw, bench-top light exposure), and solubility limits in relevant media.
For mechanistic assays, confirm reversibility (jump-dilution), time-dependence of inhibition, and potential covalency (MS adducts) as appropriate to the chemical class (once known).
Because no synthetic or functional group information is supplied, specific named-reaction utility is not addressed for this item.
Reaction Conditions
Reaction conditions are not applicable in the absence of structural information and intended synthetic transformations.
General notes (when structure becomes available):
For fragile motifs (e.g., aryl nitro, anilides, benzyl ethers), avoid strong acids/bases and prolonged high temperatures.
For heteroaromatics susceptible to oxidation, conduct manipulations under inert atmosphere and protect from light as already advised for this item.
Verify stability in common solvents (DMSO, MeCN, MeOH, THF) across temperature ranges used in analytics (autosampler at 4–10°C vs. ambient).
At present, consult the CoA/SDS for any specific incompatibilities.
Safety and Handling
Safety information specific to this item has not been provided.
GHS Classification / Pictograms / Signal Word / H-Statements: Not specified for this item; refer to SDS.
Primary storage conditions (provided): Store at 2–8°C, protected from light, desiccated. Shipped on wet ice.
General laboratory precautions for small organic molecules (consult the SDS for definitive guidance):
PPE: Lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Handle powders in a fume hood to avoid inhalation.
Avoid: Contact with oxidizers or strong acids/bases until compatibility is known. Prevent moisture ingress for moisture-sensitive materials.
Light sensitivity: Protect solutions and solids from ambient light as indicated; use amber vials or foil wrap.
Hygroscopicity: Store desiccated; open vials briefly in low-humidity environments. Backfill with inert gas if noted on the CoA.
First aid (overview): In case of skin/eye contact, rinse with water for ≥15 min; if inhaled, move to fresh air; if ingested, seek medical attention. Provide SDS to responders.
Waste: Dispose via approved organic waste streams; do not release to drains. Decontaminate glassware with compatible solvents.
Always defer to the product-specific SDS and institutional EHS policies.
Solvent Selection
Because the chemical structure and solubility data are not provided, choose solvents empirically with an assay-driven approach.
General strategy for small-molecule screening compounds:
Primary reconstitution solvent: Anhydrous DMSO (typical stock 10–50 mM). If solubility is insufficient, test DMF or NMP as alternates, noting higher toxicity/viscosity.
Polar protic options:MeOH or EtOH for UV-transparent work; confirm chemical stability against transesterification or solvolysis if functional groups could be labile (determine after structure is known).
Aqueous delivery: Dilute DMSO stocks into buffered media; maintain final DMSO ≤0.5–1% v/v to minimize assay interference. Use surfactants (e.g., 0.01–0.05% Tween-20) sparingly to mitigate aggregation if needed.
Insoluble/greasy chemotypes: Consider 2-propanol, acetonitrile, or co-solvent blends (ACN:H2O with 0.5–2% DMSO) for analytical injections.
Quick comparison (general):
DMSO: highest solvating power, high boiling point, miscible with water; may affect some enzymes/cells at >1%.
DMF/NMP: strong solvents but with higher toxicity; reserve for stubborn cases and remove before bioassays.
MeOH/EtOH: greener and volatile; limited for very lipophilic compounds.
Always confirm absence of precipitation by visual check and analytical methods (HPLC-UV baseline, light scattering) after dilution.
Storage and Reconstitution
Provided storage conditions and recommended handling for research use.
Storage conditions (as provided): Store at 2–8°C, protected from light, desiccated.
Shipping: On wet ice.
Container: Keep tightly closed; prefer amber vials or foil-wrapped containers to limit light exposure.
Reconstitution guidance (general):
Reconstitute in anhydrous DMSO to prepare a 10–50 mM stock unless the CoA specifies otherwise. If insoluble, screen alternative solvents (DMF, NMP, MeOH, EtOH) and document final solvent system.
After dissolution, aliquot into single-use volumes and store at −20°C to −80°C in amber tubes to minimize freeze–thaw and photolysis. Note: These temperatures are general best practices for DMSO stocks; follow any future item-specific guidance on the CoA.
Equilibrate frozen DMSO stocks to room temperature before opening to prevent moisture condensation; promptly re-seal under dry air or inert gas.
Inspect solutions periodically for precipitation, color change, or degradation (check by HPLC/LC-MS) and remake stocks as needed.
For authoritative, lot-specific instructions (including any hydrate/salt form), consult the product’s CoA/Spec Sheet and SDS.
Structure and Identity
Concise identity summary for a research screening compound entry.
SKU: D648409
Product Name: DC-U4106
CAS: 2410534-62-0
Category: Small molecules and compound libraries (screening compound)
Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
Structural features (general guidance):
Specific functional groups, ring systems, and stereochemical information are not provided in the current listing. For structural elucidation and informatics (e.g., substructure search, PAINS filtering), obtain the structure file (SDF/MOL) or CoA.
If you are integrating this item into a screening deck, request the structure to confirm liabilities (reactive moieties, redox-active motifs, aggregators) and to compute properties (cLogP, TPSA, HBD/HBA) for assay design.
2D/descriptor considerations (general):
For assay transfer and rule-of-five checks, compute physicochemical descriptors (cLogP, cLogS, pKa) once the structure is available. Use these to guide solvent choice and maximum DMSO carryover in biological assays.
Synthetic Utility
Specific functional groups and reactivity are not provided for DC-U4106; therefore, item-specific synthetic roles cannot be described.
General guidance when the structure is known (for future reference):
Identify key handles for diversification (e.g., aryl halides for cross-coupling, amines/acids for amide formation, heteroaryl cores for SNAr) to enable SAR expansion.
Assess chemoselectivity and protecting-group needs based on the motif distribution (alcohols, amines, acids, carbonyls).
Plan scaffold hopping and vector exploration through late-stage functionalization (C–H activation, Minisci, photoredox) if the core supports it.
Until structural information is available from the CoA/Spec Sheet, treat this item as a screening endpoint rather than a synthetic building block.
Target Specificity
No target information is provided for DC-U4106. There are no claims regarding enzyme/receptor binding, pathway modulation, or organism specificity in this listing.
Guidance for discovery workflows (general):
Use unbiased profiling (broad biochemical panels, chemoproteomics) or phenotypic screening followed by deconvolution to determine potential targets.
Confirm hits via orthogonal assays and counter-screens to exclude assay artifacts (fluorescence interference, redox cycling, aggregation).
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.